和(he)瑞基因(yin)作為貝瑞基因(yin)成員(yuan)企業創立于(yu)2017年,是一家專(zhuan)注腫(zhong)(zhong)(zhong)(zhong)(zhong)瘤(liu)(liu)(liu)全(quan)病程(cheng)的(de)基因(yin)檢(jian)測公(gong)司,在“一切腫(zhong)(zhong)(zhong)(zhong)(zhong)瘤(liu)(liu)(liu)實(shi)現早(zao)診(zhen)早(zao)治(zhi)(zhi),所有(you)患者(zhe)(zhe)獲得(de)較(jiao)好(hao)治(zhi)(zhi)療(liao)”的(de)使命下(xia),建立了針對腫(zhong)(zhong)(zhong)(zhong)(zhong)瘤(liu)(liu)(liu)中晚期(qi)患者(zhe)(zhe)治(zhi)(zhi)療(liao)的(de)完(wan)(wan)整基因(yin)檢(jian)測產(chan)品服務體系:包括靶向與免疫用藥檢(jian)測、療(liao)效監(jian)測、預后判斷(duan)等(deng)系列產(chan)品;同時,在腫(zhong)(zhong)(zhong)(zhong)(zhong)瘤(liu)(liu)(liu)早(zao)期(qi)篩查診(zhen)斷(duan)領域(yu),啟動了包括肝癌、肺癌、婦(fu)科腫(zhong)(zhong)(zhong)(zhong)(zhong)瘤(liu)(liu)(liu)等(deng)一系列早(zao)篩早(zao)診(zhen)臨床(chuang)研究項目;完(wan)(wan)成了兩地(福州、北(bei)京)三中心(實(shi)驗、超算、研發)的(de)布局;著力(li)于(yu)為臨床(chuang)腫(zhong)(zhong)(zhong)(zhong)(zhong)瘤(liu)(liu)(liu)治(zhi)(zhi)療(liao)和(he)個人健康(kang)管理提(ti)(ti)供(gong)更好(hao)的(de)腫(zhong)(zhong)(zhong)(zhong)(zhong)瘤(liu)(liu)(liu)基因(yin)檢(jian)測服務,合作和(he)服務網絡(luo)覆(fu)蓋(gai)全(quan)國400多家三甲醫院,已為數十萬腫(zhong)(zhong)(zhong)(zhong)(zhong)瘤(liu)(liu)(liu)患者(zhe)(zhe)提(ti)(ti)供(gong)了有(you)價值的(de)腫(zhong)(zhong)(zhong)(zhong)(zhong)瘤(liu)(liu)(liu)基因(yin)檢(jian)測服務。